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LETTERS TO THE EDITOR
Thrombolysis, the Risk of Rupture and
Other Risks
If results of a retrospective study contradict results of randomized
trials, methodology must be scrutinized. Without randomization there
are often many alternative explanations of observations.
In an analysis of .350,000 patients participating in the United
States National Registry of Myocardial Infarction, Becker et al. (1)
showed that thrombolytic agents, previous myocardial infarction and
intravenous beta-adrenergic blocking agents are independently associ-
ated with cardiac rupture. These findings raise several issues of study
design and interpretation.
Electromechanical dissociation and rupture were the cause of
death in 7.3% of patients in this study. Similar, extremely low rates
were also reported in articles published between 1938 and 1968. Due
to a dramatic decrease in deaths due to arrythmias and deaths due to
pump failure, free wall rupture is now the cause of death in .20% of
patients (2,3). In discordance to the randomized International Study of
Infart Survival (ISIS)-I trial (4), which clearly showed that early
intravenous beta-blockade reduces the incidence of early rupture in
patients with acute myocardial infarction, Becker et al. found that
patients treated with intravenous beta-blockers had a higher incidence
of rupture. Hearts with previous infarction seem to be more resistant
to rupture according to a host of publications by pathologists (5), but
the contrary was found in the report under discussion. The risk of
electromechanical dissociation/rupture was doubled by thrombolysis in
the study by Becker et al. but was not increased in patients treated with
thrombolysis in randomized trials and meta-analyses of randomized
trials (6,7).
The obviously most important pitfalls in this study are the rather
arbitrary criteria used in the definition of causes of death. The cause of
death was based on clinical suspicion rather than on autopsy findings.
However, in patients with acute myocardial infarction, the cause of
death is always uncertain unless autopsy is performed. Subacute
ruptures making up 30% to 45% of all rupture cases may imitate other
causes of death, such as infarct extension, cardiogenic shock or death
due to arrythmias. Autopsy rate, an important variable in this context,
is not mentioned in the report but seems to be very low. In contrast, all
patients with electromechanical dissociation were included in statisti-
cal analysis and as a result were included in conclusions on heart
rupture; but electromechanical dissociation is not always a conse-
quence of rupture, and global ischemia or large infarcts are other
important causes in patients with acute myocardial infarction. The
confounding effect of these incorrect classifications may be enormous.
Therapies, such as thrombolysis, intravenous beta-blocker treat-
ment, or diagnostic modalities, such as autopsies, are not distributed in
a random manner but are limited to strictly defined and totally
different subgroups with unequal risks of rupture and unequal risks of
missing a diagnosis of rupture. Late admission after onset of symptoms
is the most frequent contraindication to thrombolysis, so that the
clustering of ruptures within the first 24 h in the thrombolysis group
may be caused by unequal observation periods. The description of the
survival analysis is not very precise in this respect.
Concerns about the risk of thrombolysis in the elderly are prevalent
among doctors in many countries, leading to shortfalls. In a recent
report (8) on the use of thrombolysis in 11 European countries, the
treatment odds ratio was only 0.24 among patients 75 to 84 years old
who were apparently suitable for thrombolysis. Because reports about
the risks of thrombolysis may have a disproportionate effect on clinical
practice, the risk of drawing conclusions from imprecise data should
also be kept in mind.
HANS POLLAK, MD
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Reply
Pollak raises several interesting questions concerning cardiac rupture.
We appreciate his insightful comments and acknowledge his prior
contribution to the field.
Cardiac rupture is a well recognized and feared complication of
acute myocardial infarction (MI). Despite descriptions dating back to
the mid-17th century (1), questions regarding its pathogenesis remain
unanswered.
The reperfusion era has raised additional questions for the medical
community to ponder. Is rupture the same as it was in the pre-
reperfusion era? What is the impact of reperfusion in general and
thrombolysis in particular? What are the contributions attributable to
thrombin inhibition or the intensity of anticoagulation? Most impor-
tant, can rupture be prevented?
In our composite view derived from the U.S. National Registry of
Myocardial Infarction (NRMI) data base (2), rupture among patients
receiving thrombolytic therapy occurred infrequently (0.7%). Consis-
tent with the findings of randomized studies conducted in the reper-
fusion era, including the Thombolysis in Myocardial Infarction Phase
II (TIMI-II) (3) and Global Utilization of Streptokinase and TPA for
Occluded Arteries (4) studies, rupture accounted for nearly 15% of
in-hospital deaths. The use of clinical criteria, including electrome-
chanical dissociation to diagnose rupture represents a precedent set by
previous investigators (5) who meticulously correlated clinical infor-
mation and pathologic observations (6,7). We potentially underesti-
mated the overall occurrence of rupture by relying on clinical criteria
and focusing predominantly on in-hospital cardiac events. As Pollak
points out, there may be a statistical “shift” toward early rupture as
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